The Annals of pharmacotherapy
Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review.
Danial Nasim, Brett Shaffer, Steven R Feldman
Published: 202510.1177/10600280251402987
Abstract
BACKGROUND: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-sever…
Preview only. Read the full abstract at the source